NOVO-OFLOXACIN 300 MG — DIN 02243475
OFLOXACIN : 300 MG · NOVOPHARM LIMITED · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is NOVO-OFLOXACIN?
NOVO-OFLOXACIN 300 MG contains OFLOXACIN : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02243475, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 08-May-2012. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NOVO-OFLOXACIN used for?
NOVO-OFLOXACIN (ofloxacin) Tablets are indicated for the treatment of adults with various infections. These include lower respiratory tract infections (pneumonia and acute exacerbation of chronic bronchitis), urinary tract infections (uncomplicated cystitis and complicated urinary tract infections), prostatitis, sexually transmitted diseases (acute, uncomplicated urethral and cervical gonorrhea, cervicitis/urethritis due to Chlamydia trachomatis or mixed infections, and acute pelvic inflammatory disease of mild to moderate severity), and skin and skin structure infections (uncomplicated skin and skin structure infections).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ofloxacin cost around the world?
Ofloxacin is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 39 | USD███.██ |
| South Africa | single exit price | 10 | 12 | ZAR███.██ |
| Saudi Arabia | public | 11 | 11 | SAR███.██ |
| Romania | max producer price | 6 | 6 | RON███.██ |
| Bahrain | retail (max) | 5 | 5 | BHD███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
83 pack listings across 43 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Ofloxacin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Ofloxacin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Ofloxacin, across 10 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 3 | 0 | OFLOXACIN TABLETS | No marketed DIN |
| JANSSEN INC | 3 | 0 | FLOXIN TABLETS 200MG, FLOXIN TABLETS 300MG, FLOXIN TABLETS 400MG | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-OFLOXACIN | No marketed DIN |
| ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC. | 1 | 0 | FLOXIN I.V. LIQ 20MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 200 mg - Available in bottles of 50, 100, 500, and 1000 tablets. 300 mg - Available in bottles of 50, 100, 500, and 1000 tablets. 400 mg - Available in bottles of 50, 100, 500, and 1000 tablets. |
| Storage | Store at room temperature (15-30°C). Protect from light. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Ofloxacin |
|---|---|
| ATC code | J01MA01 |
| AHFS class | 08:12.18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243475 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243475 |
| Brand name | NOVO-OFLOXACIN |
| Generic / active ingredient | OFLOXACIN : 300 MG |
| Market authorization holder | NOVOPHARM LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J01MA01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01MA |
| Current status | CANCELLED POST MARKET |
| Status date | 08-May-2012 |
| Original market date | 2004-06-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
200 mg to 400 mg orally every 12 hours depending on infection type. Adjust dose for renal impairment (CrCl <= 50 mL/min). Max 400 mg/day in severe cirrhosis.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
History of hypersensitivity to ofloxacin or members of the quinolone group of antibacterial agents.
Warnings and precautions
Risk of tendonitis/rupture, CNS effects (convulsions, psychosis), hypersensitivity (anaphylaxis), and pseudomembranous colitis. Not effective for syphilis. Avoid excessive sunlight.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FLOXIN I.V. LIQ 20MG/ML | 20 MG | LIQUID | ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC. | CANCELLED PRE MARKET | 02049414 |
| FLOXIN TABLETS 200MG | 200 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 01968424 |
| FLOXIN TABLETS 300MG | 300 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 01968416 |
| FLOXIN TABLETS 400MG | 400 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | 01968408 |
| NOVO-OFLOXACIN | 400 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02243476 |
| NOVO-OFLOXACIN | 200 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | 02243474 |
| OFLOXACIN TABLETS | 400 MG | TABLET | AA PHARMA INC | CANCELLED POST MARKET | 02231532 |
| OFLOXACIN TABLETS | 200 MG | TABLET | AA PHARMA INC | CANCELLED POST MARKET | 02231529 |
| OFLOXACIN TABLETS | 300 MG | TABLET | AA PHARMA INC | CANCELLED POST MARKET | 02231531 |
2 · Same class — other molecules in ATC J01MA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ciprofloxacin | ACT CIPROFLOXACIN · AG-CIPROFLOXACIN · APO-CIPROFLOX · AURO-CIPROFLOXACIN · +50 more | 139 | 29 | Yes |
| Levofloxacin | ACT LEVOFLOXACIN · APO-LEVOFLOXACIN · AURO-LEVOFLOXACIN · AVA-LEVOFLOXACIN · +19 more | 54 | 16 | Yes |
| Moxifloxacin | AG-MOXIFLOXACIN · APO-MOXIFLOXACIN · APO-MOXIFLOXACIN HYDROCHLORIDE · AURO-MOXIFLOXACIN · +20 more | 25 | 8 | Yes |
| Delafloxacin | BAXDELA | 2 | 2 | Yes |
| Norfloxacin | AVA-NORFLOXACIN · CO NORFLOXACIN · NORFLOXACIN · NORFLOXACINE-400 · +5 more | 12 | 1 | Yes |
| Ofloxacin | FLOXIN I.V. LIQ 20MG/ML · FLOXIN TABLETS 200MG · FLOXIN TABLETS 300MG · FLOXIN TABLETS 400MG · +2 more | 10 | 0 | Not in Canada |
| Gatifloxacin | NOVO-GATIFLOXACIN · TEQUIN · TEQUIN IV | 5 | 0 | Not in Canada |
| Trovafloxacin | TROVAN I.V. · TROVAN TABLETS 100MG · TROVAN TABLETS 200MG | 3 | 0 | Not in Canada |
| Grepafloxacin | RAXAR | 1 | 0 | Not in Canada |
| Gemifloxacin | FACTIVE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01M
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01MB | Nalidixic Acid | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NOVO-OFLOXACIN called?
The same molecule, Ofloxacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Tafloc | Latin | South Africa |
| Ocuflox | Latin | Australia |
| DEXAFLOX | Latin | Bahrain |
| DEXAFLOX OPHTHALMIC SUSPENSION | Latin | Saudi Arabia |
| Exocin | Latin | South Africa |
| LOXTRA | Latin | Bahrain |
| LOXTRA EYE DROP | Latin | Saudi Arabia |
| NOVECIN | Latin | Bahrain |
| OFLOXACIN | Latin | Bahrain |
| Oflox™ | Latin | United Arab Emirates |
| OPTIFLOX | Latin | Bahrain |
| OPTIFLOX OPTHALMIC SOLUTION | Latin | Saudi Arabia |
| Optiflox™ | Latin | United Arab Emirates |
| OXACIN | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.